Supplementary table S1: Institutional protocol for categorization and management of patients with COVID-19

RAJIV GANDHI GOVT. GENERAL HOSPITAL &MADRAS MEDICAL COLLEGE , CHENNAI

PARAMETERS	SEVERE	MODERATE	MILD	ASYMPTOMATIC
Spo2*	<90%in RA requiring 02	<94% in Room air requiring O2	94 -97% in RA	>97% in RA with normal RR
RR	>30	24-30	<24	

NLR	>7	>5	>3.13	IF INVESTIGATIONS ARE WITHIN LIMITS 1. <55 YEARS WITH NO COMORBIDITY REFER TO COVID CARE CENTER 2 >55 YEARS WITH COMORBIDITY REFER TO COVID HEALTH CENTER
CRP (mg/l)	>100	50-100	10-50	
FERRITIN(ng/ml)**	>1500 (F - >1000)	600-1500 (F- 500-1000)	400-600 (F- 150-500)	
LDH (IU/L	>500	300-500	220-300	
D DIMER mic /ml)	>1.0	0.5-1.0	<0.5	
IL6(pg/ml)	>100	20 - 100	8-20	
CT CHEST	**75%-100%**	**25-75%**	**< 25%**	

SPO_2TARGET	90-94%		94-96%		94-96%	O2 FLOW CHART IN ANNEXURE I
OXYGEN DEVICES	NRM	8-15 LTS	MASK	5-8 LTS	MONITOR SPO2 Q4H,IF SPO_2 DROPS <94% START 3-5 LTS VIA MASK	
	HFNO	30-70 LTS	NRM	8- 15 LTS		
	CPAP	5-12 CM H2O				

DRUGS	SEVERE			MODERATE		MILD		
MEDICINE	Dose	Fre	Days	MEDICINE	Dose	MEDICINE (**oral**)	Dose	Frequency
ENOXAPARIN**	40 mg	BD	7-10	**ENOXAPARIN****	40 MG	PARACETAMOL	500 mg	SOS
DEXA	8 mg	OD	7	**DEXA**	8 mg (3-5 days)	AZITHROMYCIN	500 mg ST	250 for 4 days OD
CEFTRIAXONE	2 gm	OD	5-7	**CEFTRIAXONE**	2GMS	VIT C	500 mg	OD
VIT C	1 gm	OD	5	**PANTAPRAZOLE**	40 MG	ZINC (elemental)	50 mg	OD
THIAMINE	200mg	OD	5			PANTAPRAZOLE	40 mg	OD
PANTAPRAZOLE	40 mg	OD	5	**REMDESIVIR**** *		ADEQUATE HYDRATION ORALLY ENCOURAGED		
TOZULICIMAB	400 mg	2 doses 12 hrs apart		**TOZULICIMAB****	400 mg(1dose) 2ND Dose ±			
REMDESIVIR								

LAB TESTS	SEVERE	MODERATE	MILD
CBC	**48 HRS**	**48 HRS**	**48 HRS**
RLE	**48 HRS**	**48-72 HRS**	**72 HRS**
COVID PROFILE	**48 HRS**	**48- 72 HRS**	**72 HRS**
D-DIMER	**72 HRS**	**48 HRS**	**72 HRS**
PROCALCITONIN	**72 HRS /SOS**	**SOS**	**-**
LACTATE	**72 HRS/SOS**	**SOS**	**-**
IL6	**-**	**24**	**-**
CXR - BED SIDE	**CLINICALLY INDICATED**	**IF CLINICALLY INDICATED**	**IF CLINICALLY INDICATED**
OTHERS LIKE TROPONIN, pro BNP IF CLINICALLY INDICATED			

DISCHARGE CRITERIA	1. Repeat swab negative 2. Without o2 support for 4 days	1.STABLE AND WITH OUT OXYGEN SUPPORT FOR 4 DAYS	IF STABLE REFER TO COVID HEALTH CENTRE AFTER 5 DAYS OF MONITORING FOR FURTHER OBSERVATION

ARDS: New or worsening respiratory symptoms unrelated to cardiac or other causes with PEEP of 5MM HG 1. MILD: P/F<300 or SPO2/FIO2 <315 2.MODERATE: P/F <200 or SPO2/FIO2 235. 3.SEVERE .P/F <100 or SPO2/FIO2:<150 if HFNO and CPAP
fails treat with low tidal volume 6 ml/kg RR 20-35/mt with plateau pressure around 30. Prone ventilation advised in refractory hypoxemia

Acute life threatening organ dysfunction like decreased urine output, acidosis, high lactate, altered LFT(sepsis)and hypotension despite volume resuscitation requiring vasopressors (septic shock) with high lactate level and procalcitonin should be treated accordingly by escalating antibiotics, careful fluid therapy.
GENERAL MEASURES: 1.ECG for all patients. 2. Strict diabetic Control as per guidelines issued in Annexure III. 3. Advise to get oxygenated in prone position with the pillow in longitudinal position.(ANNEXURE II) 4.High protein diet 5.Maintain adequate hydration fluids NS after clinical assessment of volume status 6.Completebedrest 7. ABG as and when required.
*FOR COPD: SPO2 OF 2-4% lower values are acceptable *FERRITIN **LMWH. 1.For enoxaparin if increased renal parameters once daily can be given 2.For deltaparin 5000 units can be given once daily 3.CI : plt < 25000, evidence of active bleeding ***TOZULICIMAB.1.400 mg diluted in 100 ml ns given over 1 hour 2. Repeat dose after 12 hours CI: immunosuppressive states, PLHA, active bacterial fungal infections. (Start if 3 out of five markers present)**********REMDESIVIR**: (better, if started early in the course of illness) 1. 200 mg in 250 normal saline over 4 hours on first day 2. 100 mg in 100ml NS infusion from 2nd day onwards for 5 days 3. If on ventilatory support continue for another 5 days 4. To monitor RLE every 48- 72 hrs. : contraindications 1. ALT> 5 times 2. Pregnancy, Lactation 3. Caution in Sr. Creatinine clearance <30ml/mt

Supplementary figure S2: Comparison of oxygen requirement of patients during hospitalisation



Supplementary figure S3: Survival of patients admitted with moderate and severe disease



Cumulative survival of patients with moderate and severe disease

Days	D2	D3	D7	D12	D17	D22	D27	D32	D35
Moderate (n=21)	21	21	21	20	20	20	20	20	20
Severe (n=27)	27	26	24	21	20	20	19	18	18